Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: Results of a multicenter early phase II study

D. H. Lee, S. W. Kim, C. Suh, Jay S. Lee, J. H. Lee, S. J. Lee, B. Y. Ryoo, K. Park, J. S. Kim, D. S. Heo, N. K. Kim

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

Background: Belotecan (Camtobell®, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). Patients and methods: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m2/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. Results: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. Conclusion: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalAnnals of Oncology
Volume19
Issue number1
DOIs
Publication statusPublished - 2008 Jan

Keywords

  • Belotecan
  • Single agent
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: Results of a multicenter early phase II study'. Together they form a unique fingerprint.

Cite this